
Barclays raised the firm’s price target on Smith & Nephew to 1,040 GBp from 1,020 GBp and keeps an Underweight rating on the shares. Published first on TheFly – the
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SNN | Smith & Nephew Snats | 30.32 | -1.19 | -3.78% |
| Name | Price | % Change | |
|---|---|---|---|
| $30.32 | -3.78% |

Barclays raised the firm’s price target on Smith & Nephew to 1,040 GBp from 1,020 GBp and keeps an Underweight rating on the shares. Published first on TheFly – the

Smith & Nephew Snats ( ($SNN) ) has shared an announcement. Smith & Nephew plc disclosed on Nov. 18, 2026, that directors and persons discharging managerial responsibilities participated in its

An update from Smith & Nephew Snats ( ($SNN) ) is now available. Smith & Nephew plc, identified in the filing as a foreign private issuer, has its principal executive

WSW, NY, November 10th, 2026, FinanceWire Without the deal, Smith+Nephew leans harder on what it already owns, including SANTYL, a $400 million wound drug its own CEO calls slow. MediWound

Canaccord raised the firm’s price target on Smith & Nephew to $33 from $30 and keeps a Hold rating on the shares. The firm said they delivered another challenged quarter

Analyst Julien Ouaddour from Bank of America Securities reiterated a Hold rating on Smith & Nephew and increased the price target to p1,150.00 from p1,100.00. Julien Ouaddour has given his

Smith & Nephew Snats ( ($SNN) ) has shared an update. Smith+Nephew is a medical technology company focused on orthopaedics, sports medicine, ear, nose and throat products, and advanced wound

An announcement from Smith & Nephew Snats ( ($SNN) ) is now available. Smith & Nephew is a medical-technology company serving global healthcare markets. Its portfolio covers sports medicine, orthopaedics,

Citi analyst Veronika Dubajova lowered the firm’s price target on Smith & Nephew to 1,380 GBp from 1,550 GBp and keeps a Buy rating on the shares. Published first on

The latest announcement is out from Smith & Nephew Snats ( ($SNN) ). Smith & Nephew plc is a global medical technology company serving the orthopedic reconstruction, advanced wound management
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 1, 2027TBA | $12.72B | $0.65 | $1.76B | 0.41 | 20.02 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.